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ABSTRACT

SEARCHING FOR NOVEL LIGANDS FOR THE CANNABINOID
AND RELATED RECEPTORS

Pritesh Prakash Kumar
September 14,2011

A cell-based, Homogenous Time Resolved Fluorescence (HTRF) method was
optimized and used to test a library of 60 putative endocannabinoids for activity towards
CB1 or CB2, and to test cannabinoid ligands and fatty acid amides for GPRl19 by
measuring cAMP levels in this study. The Z' factors for the assay were greater than 0.5
for all three receptors and the assay was able to can tolerate up to 1% DMSO
demonstrating a robust and suitable technology for screening. The known cannabinoid
and

GPRl19

agonists

exhibited

the

rank

order

of potency

expected

for

CB1/CB2/GPRl19. Our data demonstrate that none of the amides, N-acyl amino acids
(glycine and alanine) Acyl-dopamines, and Acyl-GABAs was able to activate either CB1
or CB2. However the ethanoamides Dihomo-gamma-linolenoyl ethanolamide (DLEA)
and DTEA Docosatetra-7Z,1 OZ, 13Z, 16Z-enoyl ethanolamide (DTEA) were found to
activate CB 1 and CB2. Our data provide direct evidence to support the hypothesis that
unsaturation in the acyl chain of fatty acid ethanolamides affects the ability of these

v

compounds to activate GPRl19. Our results suggested that GPRl19 activation requires
certain structural requirements for the charged head groups of the fatty acid amides.
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CHAPTER!
INTRODUCTION
Marijuana (Cannabis sativa) is one of the oldest and most widely abused drugs,
which has also been used for medicinal purposes by various cultures. The primary
psychoactive constituent of marijuana is ~9-tetrahydrocannabinol (~9-THC) (Gaoni and
Mechoulam, 1971). The recognized central nervous system (CNS) responses to
cannabinoids include alterations in cognition, memory, and motor function and
dysphoria/euphoria, and sedation (Hollister, 1986).
In addition to psychotropic activity, ~9 -THC and other cannabinoids produce a
variety of effects with therapeutic potential, e.g., analgesia, anti-nausea, anti-convulsion,
anti-inflammation and lowering intraocular pressure (Goutopoulos and Makriyannis,
2002; Hollister, 1986). During the past two decades, a major investigative effort on the
mechanisms of action of cannabinoids has been launched. Cannabinoids have been found
to act through G-protein coupled receptors on cell membranes (Childers and Breivogel,
1998; Childers and Deadwyler, 1996; Devane et a1., 1988; Howlett, 1995). Several
cDNAs and genes encoding cannabinoid (CB) receptors have been cloned, including CBl
and CB2 (Matsuda et a1., 1990; Mumo et a1., 1993). Endogenous cannabinoid ligands
have been isolated from the brain (Devane et a1., 1992a); high affinity cannabinoid
mimetics with a variety of chemical structures have been synthesized, and subtypeselective ligands for cannabinoid receptors are becoming available (Huffinan, 2000;
Palmer et a1., 2002).

Cannabinoid Receptor Expression
CB 1 receptors are primarily distributed in the CNS (brain and spinal cord) and
peripheral nervous system (Grotenhermen, 2004). CBl receptor expression has also been
found in several peripheral organs and tissues including endocrine glands, leukocytes,
spleen, heart and parts of the reproductive, urinary and gastrointestinal tracts
(Grotenhermen, 2004). In the CNS, CBl is highly expressed in the basal ganglia, globus
pallidus, entopeduncular nucleus, substantia nigra pars reticulata, caudate-putamen,
cerebral cortex, cerebellum, hippocampus and dorsal primary afferent spinal cord regions
(Pertwee, 2005).
CB2 receptors are primarily located in immune cells, which include neutrophils,
monocytes, natural killer cells, T cells, B cells, macrophages, mast cells, and microglia
(Pertwee, 2005). CB2 receptors have also been detected in the spleen and tonsils
(Pertwee, 2005). CB2 is thought to mediate many of the immumnomodulatory properties
produced by cannabinoids.
Cannabinoid Receptor Signaling
The cannabinoid receptors activate multiple signal transduction pathways. CB 1
and CB2 receptor agonists inhibit forskolin-stimulated adenylyl cyclase by activation of a
pertussis toxin-sensitive G-protein (Felder et aI., 1995). Stimulation of adenylyl cyclase
has been reported in pertussis toxin-treated cells, suggesting that in the absence of
functional

Gila

coupling, the CBl receptor can activate Gs (Felder et aI., 1998; Glass and

Felder, 1997; Maneuf and Brotchie, 1997). It has been reported that activation of the CB2
receptor can produce stimulation of cAMP formation, as well (Rhee et aI., 1998). Both
CB 1 and CB2 receptors are also coupled to the MAP kinase cascade via Gila proteins
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(Bouaboula et aI., 1995). In heterologous cells, CB 1 but not eB2 receptors inhibit L-, N-,
P-, and Q- type calcium channels and activate inwardly rectifying potassium channels
(Caulfield and Brown, 1992; Felder et aI., 1995; Gebremedhin et aI., 1999; Henry and
Chavkin, 1995; Mackie and Hille, 1992; Mackie et aI., 1995; Pan et aI., 1996).
Exogenously expressed CBl receptors couple to the inwardly rectifying GIRK channels
in AtT -20 pituitary tumor cells in a pertussis toxin-sensitive manner, indicating that Gila
proteins serve as transducers of the response (Henry and Chavkin, 1995; Mackie et aI.,
1995). Inhibition of calcium channels and enhancement of inwardly rectifying potassium
currents are pertussis toxin-sensitive, but independent of cAMP inhibition, suggestive of
a direct G protein mechanism (Mackie and Hille, 1992; Mackie et aI., 1995).

Cannabinoid Receptor Agonists
Based on their chemical structures, cannabinoid agonists can be classified into at
least four groups: the classical cannabinoids such as (- )_~9 -THC and HU -210 (Little et
aI., 1989; Mechoulam et aI., 1988), the non-classical cannabinoids typified by CP-55,940
(D'Ambra et aI., 1992; Melvin et aI., 1995), the aminoalkylindoles (AAIs) typified by
WIN-55,212-2 (Compton et aI., 1992; Ward et aI., 1990) and the endogenous
cannabinoids. The non-classical cannabinoids clearly share many structural features with
the classical cannabinoids, e.g. a phenolic hydroxyl at C-l (C2 '), and alkyl side chain at
C-3 (C-4'), as well as, the ability to adopt the same orientation of the carbocyclic ring as
that in classical cannabinoids (Reggio et aI., 1993). The AAIs, on the other hand, bear no
obvious structural similarities with the classical/non-classical cannabinoids.
The first identified endogenous cannabinoid ligand, isolated first from brain, was
arachidonylethanolamide (AEA, also called anandamide) (Devane et aI., 1992b). sn-2-
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arachidonyl glycerol (2-AG); was first isolated from intestinal tissue and shown to be a
second endogenous cannabinoid ligand (Mechoulam et aI., 1995). 2-AG has been found
to be present at concentrations 170 times greater than anandamide in the brain (Stella et
aI., 1997). In addition, the fatty acid glycerol ether, 2-arachidonyl glyceryl ether has been
suggested to be another endogenous cannabinoid ligand (Stella et aI., 1997).
The cannabinoid agonists have been shown to have potential therapeutic uses as
appetite stimulants, analgesics, anti-emetics, anti-spasmodic, anti-proliferative, antiinflammatory, and anti-glaucoma agents (Goutopoulos and Makriyannis, 2002; Hollister,
1986; Pertwee, 2000; 2001 a; b; Piomelli et aI., 2000; Sanchez et aI., 2001). The side
effects accompanying the therapeutic responses of cannabinoid agonists include
alterations in cognition, memory, and motor functions, dysphoria/euphoria, and sedation
(Abood and Martin, 1992; Hollister, 1986).

Cannabinoid Receptor Antagonists
Rinaldi-Carmona and co-workers at Sanofi developed the first CB 1 antagonist,
SR141716A (Rinaldi-Carmona et aI., 1994). SR141716A displays nanomolar CBl
affinity (Ki =1.98± 0.13 nM), but very low affinity for CB2. In vitro, SR141716A
antagonizes the inhibitory effects of cannabinoid agonists on adenylyl cyclase activity in
rat brain membranes. SR141716A also antagonizes the pharmacological and behavioral
effects produced by CBI agonists after interperitoneal or oral administration (Barth and
Rinaldi-Carmona, 1999). Other CBI antagonists have been reported, including AM-630
(Hosohata et aI., 1997a; Hosohata et aI., 1997b; Pertwee et aI., 1995), LY-320135 (Felder
et aI., 1998) and 0-1184 (Ross et aI., 1998).
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Rinaldi-Cannona and co-workers at Sanofi also reported the first CB2 antagonist,
SR144528 (Barth and Rinaldi-Cannona, 1999; Rinaldi-Cannona et al., 1998). SR144528
displays sub-nanomolar affinity for both the rat spleen and cloned human CB2 receptors
(Ki = 0.60±0.13 nM). SR-144528 displays a 700-fold lower affinity for both the rat brain

and cloned human CB 1 receptors.
There is strong evidence in the cannabinoid literature that SR141716A and
SR144528 can act as inverse agonists. Moreover, both CB1 and CB2 receptor-transfected
cells exhibit high constitutive activity (Bouaboula et al., 1999; Bouaboula et al., 1997).
This constitutive activity can be blocked by the CB1-selective SR141716A and CB2selective SR144528, respectively. Recently, therapeutic applications for cannabinoid
inverse agonists are emerging in the literature. For example, the CB1 inverse agonist,
SR 141716A has been developed as an appetite suppressant.

The Cannabinoid Related Receptor: GPRl19
Type 2 diabetes (T2D) and associated obesity are growing public health concerns
(Shah, 2009). As a result, many phannaceutical companies have focused their efforts to
discover novel, orally effective agents that can modulate glucose homeostasis with a
concurrent reduction in body weight. GPR119 is a member of the rhodopsin family ofG
protein-coupled receptors. Recently GPR119 has emerged as a promising therapeutic
target for both T2D and obesity (Overton et al., 2008).

GPR119 Structure
Homology clustering analysis revealed that the closest relatives ofGPR119 are
the cannabinoid receptors (Overton et al., 2006). In addition, through phylogenetic
analysis, Godlewski et al 2009 placed GPR119 to the MECA (melanocortin; endothelial
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differentiation gene; cannabinoid; adenosine) receptor cluster and confirmed that the
closest relatives of GPR119 are CB 1 and CB2 cannabinoid receptors (Godlewski et aI.,
2009).

GPRl19 Receptor Expression
GPR119 is primarily expressed in pancreatic beta-cells and enteroendocrine cells
of the gastrointestinal tract (GI) (Chu et aI., 2007b; Lauffer et aI., 2009; Soga et aI.,
2005). Immunohistochemical and autoradiographic data demonstrate that GPR119 is
mainly localized to a subset of cells in the pancreatic islets of Langerhans where it was
found to co-localize with insulin (Chu et aI., 2007b). GPRl19 immunoreactivty was also
found in the small intestine where it co-localizes with glucagon-like-peptide-l (GLP-l)
(Chu et aI., 2007b). In addition, GPR119 has been found in the following pancreatic beta
cell lines: NIT-I, MIN6, RIN5, HIT-TIS (Chu et aI., 2007b; Lan et aI., 2009; Ning et aI.,
2008; Reimann et aI., 2008; Soga et aI., 2005). Furthermore, GPR119 was found in
enteroendocrine L-cell models such as FRIC, mGLUTag, and hNCI-H716 and in mouse
L-cell primary cultures (Chu et aI., 2007b; Lan et aI., 2009; Ning et aI., 2008; Reimann et
aI., 2008; Soga et aI., 2005).
Although it has not been detected in the human CNS, GPR119 expression has
been detected in several regions of the rat brain, including cerebellum, cerebral cortex,
choroid plexus, hippocampus and hypothalamus (Jones et aI., 2009).

GPR119 Receptor Signaling
GPRl19-expressing cells display a constitutive increase in intracellular cAMP
suggesting that this receptor is coupled to the stimulatory G-protein (Gs) (Chu et aI.,
2007b). It has been shown that GPRl19 agonists activate adenylyl cyclase, increase
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cAMP, and increase protein kinase A activity in GPRl19-expressing cells (Chu et aI.,
2007b; Lauffer et aI., 2009; Reimann et aI., 2008; Semple et aI., 2008; Soga et aI., 2005).
In addition to Gs coupling, there is evidence for GPRl19-mediated activation of ATPsensitive K + and voltage-dependent Ca2+ channels (Ning et aI., 2008).

GPR119 Endogenous Agonists
Oleoylethanolamide (OEA) was the first putative endogenous fatty acid
ethanolamide ligand reported for GPRl19 (Overton et aI., 2006). Overton and coworkers
have also tested the endogenous cannabinoid agonist AEA and the saturated fatty-acid
ethanolamide palmitoylethanolamide (PEA) for GPRl19 activity in a yeast-based assay.
Their results showed that OEA was the most efficacious to activate GPRl19, followed by
PEA and then AEA (Overton et aI., 2006).
In an attempt to identify novel ligands for GPRl19 more than 3000 endogenously
produced compounds were screened for GPRl19 activity (Chu et aI., 2010). Among the
compounds tested, several fatty acid amides were found to be active. OEA was confirmed
to be a GPRl19 agonist. Oleamide, an endogenously produced free amide displayed
agonist activity for GPRl19. In addition, N-oleoyldopamine (OLDA) activated GPRl19
with a similar potency to OEA (Chu et aI., 2010).
Very recently, Hansen et aI. (2011) indentified a dietary fat-derived naturally
occurring 2-0leoyl glycerol (2-0G), as a GPR119 agonist. It was also shown that 2-0G
administration to fasting humans led to increased glucagon-like peptide-1 (GLP-1)
secretion (Hansen et aI., 2011).
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GPR119 Synthetic Agonists
High-throughput screening in the pharmaceutical industry resulted in the
identification ofPSN632408 and AR231453, two prototypical oxadizone analogues, as
synthetic GPRl19 agonists (Semple et aI., 2008). AR231453 is notable for its nanomolar
affinity for GPR 119. Both of these compounds have been shown to increase intracellular
cAMP, and enhance the secretion of insulin and GLP-1 (Semple et aI., 2008). Currently,
the one synthetic GPRl19 agonist, APD668 (Arena Pharmaceuticals), has entered clinical
trials.

GPR119: Diabetes and Obesity
Since GPRl19 is primarily distributed in pancreatic

~-cells

and enterocrine L-

cells, it was hypothesized that this receptor may modulate glucose homeostasis and
obesity (Overton et aI., 2006).
It has been shown previously that GPRl19 agonists (synthetic and endogenous)

stimulate insulin release by at least two mechanisms (Flock et aI., 2011). The first
mechanism is that the increase in cAMP signaling directly leads to an enhanced glucosedependant insulin secretion. The second mechanism is that the increase in cAMP
signaling results in increased glucagon-like peptide 1 (GLP-1) and glucose-dependent
insulinotropic peptide (GIP) levels, which stimulates glucose-dependant insulin secretion
and also inhibits glucagon secretion, appetite, and delays gastric emptying (Lauffer et aI.,
2008).
Recently, endogenous and small molecule synthetic GPRl19 agonists have been
shown to stimulate insulin release (Chu et aI., 2007b; Overton et aI., 2006; Soga et aI.,
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2005). These data suggest that orally effective GPR119 agonists may be used to improve
glucose homeostasis.
It has been demonstrated that AR231453 increased secretion of insulin and GLP-l

in vitro (Chu et aI., 2008; Semple et aI., 2008). In addition, it has been shown that in vivo
administration of AR231453 stimulated GLP-1 secretion, as well as improved glucose
tolerance directly by acting on pancreatic

~-cells

to enhance glucose-dependant insulin

release (Chu et aI., 2008). Furthermore, the insulinotropic effect of AR231453 was
completely lost in GPRl19-deficient mice, demonstrating the involvement of GPR119
(Chu et aI., 2007a) .
It has been shown that OLDA also stimulated insulin release in HIT -T15

(Hamster insulinoma cell line) cells expressing GPR119 (Chu et aI., 2010). It was further
shown that OLDA improves glucose handling in mice in a GPRl19-dependent manner,
because OLDA increased glucose tolerance in control mice and had virtually no effect
on glucose tolerance in GPRl19-deficient mice (Chu et aI., 2010).
In addition to diabetes, GPR 119 is also a potential target for the treatment of
obesity (Overton et aI., 2006). Both the synthetic GPR119 agonist PSN632408 and the
putative endogenous GPR119 agonist OEA possess hypophagic properties (Lan et aI.,
2009; Overton et aI., 2006). In contrast to OEA, PSN632408 displayed no activity
towards Peroxisome Proliferator-Activated Receptor alpha (PPARa) (Overton et aI.,
2006). The hypophagic effects ofOEA may not be mediated by GPR119 since the effect
was the same in GPRl19-defecient mice indicating that OEA and PSN632408 do not act
through similar mechanisms (Lan et aI., 2009).
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CHAPTER 2
OPTIMIZATION, VALIDATION, AND APPLICATION OF A CELL-BASED
SCREENING TECHNOLOGY FOR SEARCHING NOVEL LIGANDS FOR
THE CANNABINOID RECEPTORS CBl AND CB2

INTRODUCTION
The cannabinoid receptors and endocannbinoids have been shown to be involved
in numerous pathological conditions (Miller and Devi, 2011). Thus, the discovery of new
cannabinoid ligands may lead to novel therapeutic approaches for a wide range of
diseases.
The purpose of this study was two-fold: 1) To develop and optimize a cell-based
cAMP assay for screening novel CB 1 and CB2 ligands; 2) To test a library of 60 putative
endocannabinoids for their activities towards CB 1 and CB2.
The first purpose of the current study was to develop and optimize an assay
appropriate for searching novel ligands for CB 1 and CB2. There are many cAMP assays
available for screening purposes. Homogenous Time Resolved Fluorescence (HTRF) is
based on the principle of competition of antibody binding sites between the native cAMP
produced by cells and the d2-labeled cAMP (Gabriel et aI., 2003). One distinct advantage
of this assay over the other technologies is HTRF's ratiometric measurement. In this
assay, measurements are taken at two wavelengths (620 and 655 nrn), which allows for
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the ratiometric reduction of data. The donor (Eu3+ Cryptate) emits at 620 nm while the
acceptor (d2) emits at 665 nm. The donor measurement serves as an internal reference
while emissions from acceptor are indicators of biological reaction. This feature is
extremely advantageous because it allows the reduction of well-to-well variation and it
eliminates the interference of compound autofluorescence. This assay has been
successfully miniaturized and still maintains accuracy and reproducibility. It is nonradioactive and does not require separation or washing steps. It is not labor intensive, is
cost-effective, and has high sensitivity in the upper femtomolar range. These qualities
make the cell-based HTRF cAMP assay the assay of choice to develop and optimize for
this thesis.
The second purpose of this current study was to test a library of 60 putative
endocannabinoids for activity towards CB 1 or CB2. We choose this library for our initial
screening experiments because all the ligands in the library are structurally related to the
endocannabinoid AEA, but each compound has some distinct structural features. These
ligands differ in their degree of saturation, fatty acid chain length, and head group
composition. The ligands consist of 10 different fatty acids with 6 different polar head
groups. Several distinct chemical classes were tested in this study, including amides,
ethanolamides, lipo-amino acids, acyl-GABAs, and acyl-dopamines. By examining the
activity of these 60 compounds towards CBl and CB2, we tested our hypothesis that
these ligands with structures related to AEA may activate these receptors.
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MATERIALS AND METHODS

Materials
Dulbecco's Modified Eagles's Medium (DMEM), penicillin/streptomycin, Lglutamine, trypsin, and geneticin were purchased from Mediatech (Manassas, VA). Fetal
Bovine Serum was obtained from Atlanta Biologicals (Lawrenceville, GA). Glass tubes
used for cAMP accumulation assays were obtained from Kimble Chase (Vineland, NJ).
These tubes were silanized by exposure to dichlorodimethylsilane (Sigma-Aldrich, St.
Louis, MO) vapor for 3 h under vacuum.
384-well, round bottom, low volume white plates were purchased from Grenier
Bio One (Monroe, NC). A cell-based cAMP HiRange kit was purchased from CisBio
International (Bedford, MA).
An endocannabinoid library containing 60 compounds pre-dissolved in DMSO
solutions was purchased from Enzo Life Sciences (Farmingdale, NY). CP-55, 940, WIN55,212-2, HU-210, 2-arachidonoyl glycerol, and anandamide were purchased from
Tocris Bioscience (Ellisville, MO). Forskolin was obtained from Sigma-Aldrich (St.
Louis, MO). RO 20-1724 was purchased from Enzo Life Sciences (Farmingdale, NY).

Cell Transfection and Culture
Human Embryonic Kidney 293 (HEK293) cells were maintained in Dulbecco's
Modified Eagle Medium (DMEM) containing 10% fetal bovine serum, 2mM glutamine,
100 units/ml penicillin, and 100 /lg/ml streptomycin in a humidified atmosphere
consisting of 5% C02, at 37°C. Expression plasmids containing the wildtype cannabinoid
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receptors were stably transfected into HEK293 cells using lipofectamine, according to
manufacturer's instructions. Stably transfected cells were selected in culture medium
containing 800 Ilg/ml geneticin. Having established cell lines stably expressing wildtype
CB 1 and CB2 receptors, the cells were maintained in growth medium containing 400
Ilg/ml of geneticin until needed for experiments.
Cell-based HTRF cAMP assay
Cellular cAMP levels were measured using reagents supplied by Cisbio
International (HTRF HiRange cAMP kit). Cultured cells were washed twice with
phosphate-buffered saline (8.1 mM NaH 2 P04 , 1.5 mM KH 2P04 , 138 mM NaCI, and 2.7
mM KCI, pH 7.2), and then dissociated in phosphate-buffered saline containing 1 mM
EDTA. Dissociated cells were collected by centrifugation for 5 min at 2000g. The cells
were resuspended in cell buffer (DMEM plus 0.2 % fatty acid free bovine serum
albumin) and centrifuged a second time at 2000g for 5 min at 4°C. Subsequently, the
cells were resuspended in an appropriate final volume of cell buffer plus the
phosphodiesterase inhibitor R020-1724 (2 IlM). 5000 cells were added at 5 III per well
into 384-well, round bottom, low volume white plates (Grenier Bio One). Compounds
were diluted in drug buffer (DMEM, plus 2.5 % fatty acid free bovine serum albumin and
2 IlM forskolin) and added to the assay plate at 5 III per well. Following incubation of
cells with the drugs or vehicle for 7 minutes at room temperature, d2-conjugated cAMP
and Europium cryptate-conjugated anti-cAMP antibody were added to the assay plate at 5
III per well. After 2 hour incubation at room temperature, the plate was read on a TECAN
GENious Pro microplate reader with excitation at 337 nm and emissions at 665 nrn and
620 nrn.
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Statistical Analysis
Data analyses were perfonned based on the ratio of fluorescence intensity of each
well at 620nm and 665 nm. Data are expressed as delta F%, which is defined as
[(standard or sample ratio - ratio of the negative control) / ratio of the negative control] x
100. The standard curves were generated by plotting delta F% versus cAMP
concentration using non-linear least squares fit (Prism software, GraphPad, San Diego,
CA). Unknowns were detennined from the standard curve as nanomolar concentrations
of cAMP. The data from the cAMP assays were

(~xpressed

as percentage of forskolin-

stimulated cAMP accumulation. After the unknowns were detennined, the sigmoidal
concentration-response equations were used (via GraphPad Prism) to detennine EC so and
Emax values of the tested compounds.
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RESULTS
Z' Factor Determination
To detennine the Z' value, experiments were perfonned in 384-well plates using
many replicates of the HTRF cell-based cAMP assay with positive and negative controls.
F or positive controls, the HEK293 cells expressing CB 1 (Fig. 2.1) or CB2 (Fig. 2.2) were
treated with the potent mixed CB1/CB2 agonist CP-55,940 at a concentration of 100 nM
for 7 minutes at room temperature. For negative controls, the cells were treated with
vehicle for 30 minutes. The Z' value was calculated using the fonnula: Z' = 1-3[(standard
deviation of negative control) + standard deviation of positive control)] I [(mean of
negative control) - (mean of positive control)] (Zhang et aI., 1999). In the current study,
the Z factor was detennined to be 0.77 and 0.79, respectively, for CB1 and CB2.

Tolerance to Dimethyl Sulfoxide (DMSO)
One important condition to define is the concentration of dimethyl sulfoxide
(DMSO) that the HTRF cAMP assay is able to tolerate without any loss in signal. For
this purpose, we tested the effect ofDMSO at concentrations ranging from 0.001 % to 100
%. In the present study, we have shown that the HTRF cAMP assay can tolerate DMSO
up to 1.0 % for both CB 1 (Fig. 2.3) and CB2 (Fig. 2.4) without any loss of signal.

Forskolin Optimization
In order to detennine the optimal forskolin concentration to be used to stimulate
cAMP production, forskolin concentration-response experiments were perfonned for
both HEK293 cells stably expressing CB 1 and HEK293 cells stably expressing CB2.
With concentrations ranging from 0.01 nM to 100 IlM, forskolin increased cAMP
accumulation in both CB I-expressing cells (Fig. 2.5) and CB2-expressing cells (Fig. 2.6).
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The forskolin ECso values for CB I-expressing cells and CB2-expressing cells were
determined to be 1.39 (0.60 to 3.00) IlM and 0.76 (0.52 to 1.10) IlM, respectively.

Pharmacological Testing of Known Cannabinoid Agonists
The ability of known cannabinoid agonists to activate cannabinoid receptors was
tested in a functional cAMP accumulation assay (HTRF) via HEK293 cells stably
expressing either CBl or CB2. As shown in Fig. 2.7, in HEK293 cells stably expressing
CBl, all five previously reported cannabinoid ligands, HU-210, CP-55,940, WIN-55,2122, AEA, and 2-AG, inhibited forskolin-stimulated cAMP accumulation in a
concentration-dependant manner, with a rank order of potency ofHU-210 > CP-55,940 >
WIN-55,212-2 > AEA = 2-AG (Table 2.1). In HEK293 cells stably expressing CB2, HU210, CP-55,940, WIN-55,212-2, AEA, and 2-AG also inhibited forskolin-stimulated
cAMP accumulation in a concentration-dependant manner (Fig. 2.8), with a rank order of
potency ofHU-210 = CP-55,940 > WIN-55,212-2 > AEA = 2-AG (Table 2.1).

Screen of a Library of Putative Endocannabinoids and The Structure-Activity
Relationships of Fatty Acid Ethanolamides in Activating CBl and CB2.
In an attempt to discover novel ligands for either CB 1 or CB2, and to examine the
structure-activity relationship of putative endocannabinoids towards these two receptors,
each compound from a chemical library containing 60 putative endocannabinoids was
tested for its ability to activate these receptors. Several distinct classes ofligands were
tested in this screen, including amides, ethanolamides, lipo-amino acids, acyl-GABAs,
and acyl-dopamines. None of the amides, lipo-amino acids, acyl.,GABAs, and acyldopamines was able to activate either CB 1 or CB2 (Data not shown). In contrast, several
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compounds in the fatty acid ethanolamide series exhibited agonist activity towards CB 1
and CB2 (Table 2.2).
Among the fatty acid ethanolamide series, AEA, Docosatetra-7Z, 1OZ, 13Z, 16Zenoyl ethanolamide (DTEA) and Dihomo-y-linolenoyl ethanol amide (DLEA) activated
both CB1 and CB2 in a concentration-dependent manner. For CB1 (Fig. 2.9), the potency
ofDLEA was similar to AEA whereas the potency DTEA was weaker than AEA. For
CB2 (Fig. 2.10), the rank order of potency is DLEA > DTEA > AEA. In addition, the
rank order of efficacy is AEA > DLEA = DTEA for CB 1 and AEA > DLEA > DTEA for
CB2. In contrast, OEA and Linoleoyl ethanolamide (LEA) displayed no agonist activity
towards either CB 1 (Fig. 2.9) or CB2 (Fig. 2.10).
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Figure 2.1. Z' factor determination. The solid symbols represent positive controls (cells
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(basal level). The Z'factor was calculated to be 0.77 for CBI.
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Figure 2.3. DMSO tolerance. HEK293 cells stably expressing either CB 1 were treated

with different concentrations of DMSO. Delta F % was calculated using the following
fonnula: Delta F % = [(standard or sample ratio -- ratio of the negative control) / ratio of
the negative control] x 100. Data shown represent the mean ± S.E.M. of three
experiments each perfonned in duplicate.
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different concentrations of DMSO. Delta F % was calculated using the following
fonnula: Delta F % = [(standard or sample ratio -- ratio of the negative control) I ratio of
the negative control] x 100. Data shown represent the mean ± S.E.M. of three
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Figure 2.7. Pharmacological testing of known cannabinoid agonists. HEK293 cells
stably expressing CB 1 were treated with different concentrations of cannabinoid agonists
HU-210, CP-55,940, WIN-55,212-2, 2-arachidonoyl glycerol, and anandamide for 7
minutes. Results are expressed as percent forskolin-stimulated cAMP accumulation. Data
shown represent the mean ± SEM of three experiments performed in duplicate.
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Figure 2.8. Pharmacological testing of known cannabinoid agonists. HEK293 cells
stably expressing CB2 were treated with different concentrations of cannabinoid agonists
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Figure 2.9. The structure-activity relationships of fatty acid ethanolamides in
activating CBt. HEK293 cells stably expressing CB 1were treated with different

concentrations of oleoyl ethanolarnide (OEA), linolenoyl ethanolamide (LEA),
docosatetra-7Z, 1OZ, 13Z, 16Z-enoyl ethanol amide (DTEA), arachidonoyl ethanolamide
(AEA), and dihomo-y-linolenoyl ethanol amide (DLEA) for 7 minutes. Results are
expressed as a percentage of forskolin-stimulated cAMP accumulation. Data shown
represent the mean ± SEM of three independent experiments performed in duplicate.
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Figure 2.10. The structure-activity relationships of fatty acid ethanolamides in
activating

CB2. HEK293 cells stably expressing CB2 were treated with different

concentrations of oleoyl ethanolamide (OEA), linolenoyl ethanolamide (LEA),
docosatetra-7Z,1 OZ, 13Z, 16Z-enoyl ethanolamide (DTEA), arachidonoyl ethanolamide
(AEA), and dihomo-y-linolenoyl ethanolamide (DLEA) for 7 minutes. Results are
expressed as a percentage of forskolin-stimulated cAMP accumulation. Data shown
represent the mean ± SEM of three independent experiments performed in duplicate.

27

Table 2.1. The effects of known cannabinoid agonists on inhibiting forskolinstimulated cAMP accumulation in HEK293 cells stably expressing CBI or CB2.
Drugs

CBI- ECso (95% CI) (nM)

CB2- EC so (95% CI) (nM)

HU-210

0.16 (0.03 to 0.695)

3.92 (1.68 to 9.15)

CP-55,940

4.91 (1.72 to 14.04)

5.15 (3.21 to 8.25)

55.36 (25.71 to 119.2)

14.69 (9.11 to 23.69)

Anandamide

1032 (356 to 3000)

290 (112 to 751)

2-Arachidonoyl
Glycerol

910 (400 to 2100)

320 (64 to 1600)

WIN-55,212-2

CI, confidence interval. Data shown are from three experiments, each performed in
duplicate.
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Table 2.2. The structure-activity relationships of fatty acid ethanolamides in
inhibiting forskolin-stimulated cAMP accumulation in HEK293 cells expressing
CBlorCB2.

Drug
Oleoyl ethanolamide (OEA)
Linoleoyl ethanolamide (LEA)
Dihomo-gamma-linolenoyl
ethanolamide (DLEA)
Arachidonoyl ethanolamide
(AEA)
Docosatetra-7Z, 1OZ, 13Z, 16Zenoyl ethanolamide (DTEA)

CBl
EC so (95% CI)(nM)
NR
NR

CB2
EC so (95% CI) (nM)
NR
NR

238 (86.1 to 658)

21.4 (13.8 to 33.2)

1165 (373 to 3643)

1239 (384 to 3994)

1870 (599 to 5837)

149 (86.2 to 258.1)

CI, confidence interval. NR, No response. Data shown are from three experiments, each
performed in duplicates.
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DISCUSSION

The purpose of this study was two-fold: 1) To optimize a cell-based, HTRF
cAMP assay for screening novel ligands for the cannabinoid receptors; and 2) To conduct
a pilot study on a library of 60 putative endocannabinoids to search for novel ligands and
to investigate the structure-activity relationships of fatty acid ethanolamides for activating
cannabinoid receptors.
Agonist binding to CB 1 and CB2 leads to Gi coupling and inhibition of adenylate
cyclase (Felder et aI., 1995). As a result, there is a decrease in intracellular cAMP levels
which was measured as an increase in HTRF signal in this study. In this study, we have
shown that the HTRF HiRange cell-based cAMP assay is a suitable technology for
screening ligands that may act on CB 1 and CB2.
The Z'factor is a standard statistical parameter used to evaluate the robustness of
a screening assay (Zhang et aI., 1999). The Z'factor value can range between 0 and 1,
with values approaching 1 indicating excellent assay robustness. A value of greater than
0.5 indicates a suitable difference between signal and background values with low
variability. In this study we determined Z'factor according to the methods published
previously (Zhang et aI., 1999). The calculated Z'factors for the cell-based cAMP assay
for CBl and CB2 receptors were 0.77 and 0.79, respectively (Figs. 2.1,2.2). These
results demonstrated that this assay is robust and suitable for screening ligands that
activate both CBl and CB2 since the determined Z'factor is greater than 0.5.
Since most chemical compound libraries come pre-dissolved in dimethyl
sulfoxide (DMSO), it is critical to determine the maximum concentration that a
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compound can be screened before DMSO reaches a concentration that is too high to be
tolerated by the assay. Therefore, we determined the effect of DMSO on the HTRF
HiRange cAMP cell-based assay. We tested DMSO at a variety of concentrations and the
results showed that the assay can tolerate DMSO up to 1 % (Figs. 2.3, 2.4). These data
indicate that the assay is suitable for screening ligands that may act on CB 1 or CB2 at a
DMSO concentration ofless than 1 %.
Since the cannabinoid receptors are negatively coupled to adenyl ate cyclase
(Felder et aI., 1995), it is necessary to first raise the cellular cAMP levels in order to
observe a robust decrease in cAMP upon ligand binding. Concentration-response studies
were performed in HEK293 stably expressing CB 1 and HEK293 cells stably expressing
CB2 to determine the optimal forskolin concentration for our screening assays (Figs. 2.5,
2.6). Based on our data, for compound screening and testing, 1 j.!M forskolin was used to
stimulate cAMP production in both the CB I-expressing and the CB2-expressing HEK293
cells.
To validate that the HTRF HiRange cell-based cAMP assay is suitable for
screening ligands that may activate CB 1 and CB2, we performed concentration-response
studies for five previously reported CBl and CB2 agonists (Figs. 2.7, 2.8). The rank
order of potencies of these known agonists in inhibiting cAMP levels in both CB 1- and
CB2-expressing HEK293 cells HU-210 > CP-55,940 > WIN-55,212-2 > AEA = 2-AG
and HU-210 = CP-55,940 > WIN-55,212-2 > AEA = 2-AG , respectively (Table 2.1).
These data are consistent with previous reports regarding the potency of these CBl and
CB2 agonists. These results also confirmed the suitability ofHTRF HiRange cell-based
cAMP assay for screening potential novel ligands for both CB 1 and CB2.
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In 1992, Devane et aI. reported AEA, a prototypical N-acyl ethanolamide (Di
Marzo et aI., 1994), as the first endogenous ligand for CBl (Devane et aI., 1992b).
Recently, several fatty acid amide derivatives have been identified in mammals in which
the ethanolamide moiety is replaced by amino acids (glycine and alanine), dopamine or
GABA to form N-acyl-amino acids (Lipo-amino acids), N-acyl-dopamines, and N-acylGABAs (Connor et aI., 2010). Since these compounds are structurally related to AEA, it
has been hypothesized that they may activate cannabinoid receptors. However, to our
knowledge, this hypothesis has not been tested thoroughly by experimental studies. In
order to test this hypothesis in a systemic and comprehensive manner, in the current study
we examined 60 putative endocannabinoids from a compound library for their ability to
activate either CB 1 or CB2. This library is designed as an array of 10 different fatty acids
and 6 different polar head groups and includes the following classes of ligands: Amides,
Ethanolamides, Lipo-amino acids, Acyl-dopamines, and Acyl-GABAs.
Our data demonstrate that none of the Amides, Lipo-amino acids (glycine and
alanine), Acyl-dopamines, and Acyl-GABAs were able to activate either CBl or CB2 in
cAMP accumulation assays. Therefore, our data disapprove the hypothesis that these
compounds are endogenous agonists for either CB 1 or CB2 in cAMP accumulation
assays. In contrast to our findings using cAMP assays, it has been reported previously
that N-arachidonoyl dopamine (NADA), one of the acyl-dopamines, was able to bind
CB 1 receptor and activates calcium mobilization in neuroblastoma cells in a fashion
consistent with CB 1 recptor activation (Bisogno et aI., 2000). Taken together, this
suggests that NADA is an agonist on CB 1 for causing calcium mobilization, but not an
agonist on CB 1 to inhibit adenylate cyclase. This type of ligand-biased signaling has been
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reported for other ligands ofG-protein coupled receptors (GPCRs) (Kenakin, 2007). It
has been suggested that GPCRs can adopt multiple conformations, leading to different
signaling events. Furthermore, it has been postulated that these different conformations
can be stabilized by different ligands, causing ligand-biased signaling (Kenakin, 2007).
In addition to AEA, the first identified endogenous agonist for cannabinoid
receptors, several other endogenous ethanolamides have been isolated and identified in
mammals (Hanus et aI., 1993). Among these endogenous ethanolamides, DLEA and
DTEA have been shown to bind CBl (Hanus et aI., 1993). In the current study we have
shown that DLEA and DTEA display similar potencies for CB 1 in cAMP accumulation
assays which is consistent with a previous report (Hanus et aI., 1993). In addition, we
have demonstrated that both of these compounds have similar efficacy as AEA to activate
CB 1 in the cAMP accumulation assays. Furthermore, we have demonstrated that the
putative endocannabinoids OEA and LEA do not activate either CBl or CB2.
Using HEK293 cells stably expressing CB2, we have found that the rank order of
potency is DLEA > DTEA > AEA, and both DLEA and DTEA have significantly lower
efficacy than AEA in inhibiting cAMP accumulation. DLEA has previously been
reported to be essentially equipotent at the CBl and CB2 receptors (Felder et aI., 1995).
To the best of our knowledge, the agonist activity ofDTEA on CB2 has not been
reported. In the current study, we have demonstrated that both DLEA and DTEA have
higher potency on CB2 than on CB 1, thus exhibiting a significant level of CB2
selectivity. In terms of efficacy, AEA was the most efficacious followed by DTEA then
DLEA. In addition, our results showed that the putative endocannabinoids OEA and LEA
do not activate CB2.
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It has previously been shown that endocannabinoids with increased saturation in
the acyl chain have decreased affinity for CB 1 (Khanolkar and Makriyannis, 1999). In
addition it has been suggested that AEA analogs with greater than 3 double bonds exhibit
significant CB 1 affinity and that the presence of 4 cis bonds is optimal (Khanolkar and
Makriyannis, 1999). OEA and LEA contain one and two double bonds, respectively, in
the acyl chain, which could be the reason why both OEA and LEA displayed no agonist
activity on cannabinoid receptors in cAMP accumulation assays. In contrast, DLEA and
DTEA have three and four double bonds respectively, which could be the reason that
both of these ligands exhibited agonist activity at CB1 and CB2 receptors in the current
study.
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CHAPTER 3

OPTIMIZATION, VALIDATION, AND APPLICATION OF A CELL-BASED
SCREENING TECHNOLOGY FOR SEARCHING FOR NOVEL LIGANDS
FOR GPRl19

INTRODUCTION

GPRl19 is a G protein-coupled receptor (GPCR) predominantly expressed in
the beta cells of the pancreas and enteroendocrine cells of the gastrointestinal tract
(Chu et aI., 2007b; Lauffer et aI., 2009; Soga et aI., 2005). GPRl19 is coupled to Gs,
so upon its activation, there is an enhancement of cAMP levels within the cell (Chu et
aI., 2007b). It has been shown previously that GPRl19 agonists stimulate insulin
release by at least two mechanisms (Flock et aI., 2011). The first mechanism is that
the increase in cAMP signaling directly leads to an enhanced glucose-dependant
insulin secretion. The second mechanism is that the increase in cAMP signaling
results in an increased glucagon-like peptide 1 (GLP-1) levels. GLP-1 is an antidiabetic hormone which stimulates glucose-dependant insulin secretion and also
inhibits glucagon secretion, appetite, and delays gastric emptying (Lauffer et aI.,
2008). It has been shown that administration of GPRl19 agonists improves glucose
tolerance in rodents (Chu et aI., 2007b; Overton et aI., 2006; Soga et aI., 2005). In

35

addition, it has been demonstrated that GPRl19 agonists decrease feeding, body weight
gain and adiposity in rats (Overton et ai., 2006) Thus, GPRl19 is a highly attractive
potential therapeutic target for both diabetes and obesity.
The first purpose of the current study is to develop an assay appropriate for
searching compounds to discover novel ligands for GPRl19. There are many cAMP
assays available for screening purposes. Homogenous Time Resolved Fluorescence
(HTRF) is based on the principle of competition of antibody binding sites between the
native cAMP produced by cells and the d2-labeled cAMP (Gabriel et ai., 2003). One
distinct advantage of this assay over the other technologies is HTRF's ratiometric
measurement. In this assay, measurements are taken at two wavelengths (620 and 655
nm), which allows for the ratiometric reduction of data. The donor (Eu3+ Cryptate) emits
at 620 nm while the acceptor (d2) emits at 665 nm. The donor measurement serves as an
internal reference while emissions from acceptor are indicators of biological reaction.
Homology clustering analysis revealed that the closest relatives of GPRl19 are
the cannabinoid receptors (Overton et ai., 2006). A separate group confirmed, through
phylogenetic analysis, that the closest relatives of GPRl19 are the cannabinoid receptors
and placed GPRl19 to the MECA (melanocortin; endothelial differentiation gene;
cannabinoid; adenosine) receptor cluster (Godlewski et ai., 2009). Based on these
observations, it has been hypothesized that synthetic cannabinoid ligands and fatty acid
amides related to endocannabinoid AEA may be potential ligands for GPRl19.
Previously, a number of cannabinoid ligands and fatty-acid amides have been
tested as potential agonists for GPRl19 (Overton et ai., 2006). However, the data from
different research groups have not always been consistent. For example, Overton and
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coworkers identified OEA as an endogenous GPRl19 ligand (Overton et aI., 2006).
However, others found that OEA does not activate GPRl19 (Brown, 2007).
It has been proposed that 1) unsaturation in the fatty acid acyl chain might be

important for activating GPRl19; and 2) there is a broad permissiveness in the aminederived moieties (the head groups) of lipid amides for being an agonist for GPR119 (Chu
et aI., 2010). However, these hypotheses either have not been examined by different
research groups or have not been tested comprehensively using novel ligands. Therefore,
the second purpose of this study is to re-examine the activity of a number of cannabinoid
ligands and fatty acid amides towards GPRl19, and to investigate, using novel
compounds that have never been tested on GPRl19, the structure-activity relationships of
the acyl side chains as well as the charged head groups in fatty acid amides for activating
GPRl19.
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MATERIALS AND METHODS

Materials

Dulbecco's Modified Eagles's Medium (DMEM), penicillin/streptomycin, Lglutamine, trypsin, and geneticin were purchased from Mediatech (Manassas, VA). Fetal
Bovine Serum was obtained from Atlanta Biologicals (Lawrenceville, GA). Glass tubes
used for cAMP accumulation assays were obtained from Kimble Chase (Vineland, NJ).
These tubes were silanized by exposure to dichlorodimethylsilane (Sigma-Aldrich, St.
Louis, MO) vapor for 3 h under vacuum. 384-well, round bottom, low volume white
plates were purchased from Grenier Bio One (Monroe, NC). A cell-based cAMP
HiRange kit was purchased from CisBio International (Bedford, MA).
CP-55,940, WIN-55,212-2, HU-210, 2-arachidonoyl glycerol, virodhamine, and
anandamide were purchased from Tocris Bioscience (Ellisville, MO). Forskolin was
obtained from Sigma (St. Louis, MO). AR231453, R020-1724 and palmitoyl
ethanolamide were purchased from Enzo Life Sciences (Farmingdale, NY). PSN632408,
Oleoylethanolamide, linoleoyl ethanolamide, dihomo-gamma-linolenoyl ethanol amide,
docosatetra-7Z,1 OZ, 13Z, 16Z-enoyl

ethanolamide,

eicosapentaenoyl

ethanol amide,

docosahexaenoyl ethanolamidel, abnormal cannabidiol, JWH200, JWHOI5, arachidonoyl
glycine, 0-1602 and 0-1918 were purchased from Cayman Chemical Company (Ann
Arbor, Michigan). N-oleoyl glycine and N-oleoyl dopamine were purchased from
Cayman Chemical Company (Ann Arbor, Michigan). Oleamide was purchased from
Tocris Bioscience (Ellisville, MO).
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Cell Transfection and Culture

Human Embryonic Kidney 293 (HEK293) cells were maintained in Dulbecco's
Modified Eagle Medium (DMEM) containing 10% fetal bovine serum, 2mM glutamine,
100units/ml penicillin, and 100

~glml

streptomycin in a humidified atmosphere

consisting of 5% CO2 at 37°C. Expression plasmid containing the GPRl19 receptor was
stably transfected into HEK293 cells using lipofectamine, according to manufacturer's
instructions. Stably transfected cells were selected in culture medium containing
800~glml

geneticin and maintained in growth medium containing 400

~glml

of geneticin

(G418) until needed for experiments.
Cell-based HTRF cAMP assay

Cellular cAMP levels were measured using reagents supplied by Cisbio
International (HTRF HiRange cAMP kit). Cultured cells were washed twice with
phosphate-buffered saline (8.1 mM NaH2P04, 1.5 mM KH2P04, 138 mM NaCl, and 2.7
mM KCI, pH 7.2), and then dissociated in phosphate-buffered saline containing 1 mM
EDT A. Dissociated cells were collected by centrifugation for 5 min at 2000g. The cells
were resuspended in cell buffer (DMEM plus 0.2 % fatty acid free bovine serum
albumin) and centrifuged a second time at 2000g for 5 min at 4°C. Subsequently, the
cells were resuspended in an appropriate final volume of cell buffer plus the
phosphodiesterase inhibitor R020-1724 (2

~M).

5000 cells were added at

5~1

per well

into 384-well, round bottom, low volume white plates (Grenier Bio One, Monroe, NC).
Compounds were diluted in drug buffer (DMEM plus 2.5 % fatty acid free bovine serum
albumin) and added to the assay plate at 5

~l

per well. Following incubation of cells with

the drugs or vehicle for 30 minutes at room temperature, D2-conjugated cAMP and
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Europium cryptate-conjugated anti-cAMP antibody were added to the assay plate at 5 III
per well. After 2 hour incubation at room temperature, the plate was read on a TECAN
GENious Pro microplate reader with excitation at 337 nm and emissions at 665 nm and
620nm.
Statistical Analysis
Data analyses were performed based on the ratio of fluorescence intensity of each
well at 620nm and 665 nm. Data are expressed as delta F%, which is defined as
[(standard or sample ratio - ratio of the negative control) / ratio of the negative control] x
100. The standard curves were generated by plotting delta F% versus cAMP
concentrations using non-linear least squares fit (Prism software, GraphPad, San Diego,
CA). Unknowns are determined from the standard curve as nanomolar concentrations of
cAMP. After the unknowns are determined, the sigmoidal concentration-response
equations were used (via GraphPad Prism) to determine EC50 and Emax values of the
tested compounds.
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RESULTS
Z' factor Determination
To determine the Z' value, experiments were performed in 384-well plates
using many replicates of the HTRF cell-based cAMP assay with positive and negative
controls (Fig. 3.1 ). For positive controls, the HEK293 cells expressing GPRl19 were
treated with the potent GPR1l9 agonist AR231453 at a concentration of 10 flM for
30 minutes at room temperature. For negative controls, the cells were treated with
vehicle for 30 minutes. The Z' value was calculated using the formula: Z' = 13[(standard deviation of negative control) + standard deviation of positive control)]/
[(mean of negative control) - (mean of positive control)] (Zhang et aI., 1999). In the
current study, the Z factor was determined to be 0.68.
Tolerance to Dimethyl Sulfoxide (DMSO)
One important condition to define is the concentration of dimethyl sulfoxide
(DMSO) that the HTRF cAMP assay is able to tolerate without any loss in signal. For
this purpose, we tested the effect of DMSO at concentrations ranging from 0.001% to
100 %. As shown in Fig. 3.2, the HTRF cAMP assay can tolerate DMSO up to 1%
without any loss of signal.
Pharmacological Testing of Known GPR119 Agonists
The ability of known agonists to activate GPRl19 was tested in a functional
HTRF cAMP accumulation assay via HEK293 cells stably expressing GPRl19. As
shown in Fig. 3.3 and Table 3.1, all three previously reported GPRl19 ligands,
AR231453 (Semple et aI., 2008), OEA (Overton et aI., 2006), and PSN632408
(Overton et aI., 2006), increase the cellular cAMP levels in a concentration-dependent
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manner, with a rank order of potency of AR231453 > OEA > PSN632408, and a rank
order of efficacy of AR231453 > OEA = PSN632408.
The Effects of Synthetic Cannabinoid Ligands on GPRl19

Three synthetic cannabinoids, CP-55,940, HU-210, and WIN-55,212-2, were
tested for their activity towards GPRl19. As shown in Table 3.2, HU-210 and CP55,940, and WIN-55,212-2 did not activate GPRl19.
The Effects of Acyl Chain Unsaturation on the Ability of Fatty Acid
Ethanolamides to Activate GPRl19

Three endogenous fatty acid ethanolamides, OEA, PEA and AEA, were tested
for their activity on GPRl19 (Fig. 3.4 and Table 3.3). All three compounds increased
cAMP levels, with EC so values not significantly different from each other. However,
our results demonstrated that OEA was the most efficacious, followed by PEA and
then AEA.

In this study, we examined the structure activity relationship on a subset of
fatty acid ethanolamides (Fig. 3.5 and Table 3). Among fatty acid ethanolamides that
we tested, LEA, and DLEA were found to be the most efficacious towards GPRl19
(Fig. 3.5). In terms of acyl chain unsaturation, LEA and DLEA contain two and three
double bonds, respectively. These two compounds had efficacy similar to those of
OEA, a putative endogenous GPRl19 ligand which contains one double bond.
On the contrary, Docosatetra-7Z,1 OZ, 13Z, 16Z-enoyl ethanol amide (DTEA),
Eicosapentaenoyl ethanolamide (EPEA) and Docosahexaenoyl ethanolamide (DHEA)
were found to have significantly reduced efficacy towards GPRl19 than OEA (Fig.
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3.5). DTEA, EPEA and DHEA contain four, five, and six double bonds in their fatty
acid acyl chain, respectively.
The effects of different head groups on the ability of oleoyl amides to activate
GPR119.

We hypothesized that different head groups on the oleoyl amides may impact
the ability of oleoyl amides to activate GPRl19. To test this hypothesis, Noleoyldopamine (OLDA), oleamide, OEA, oleoyl alanine, oleoyl glycine, and oleoyl
GABA were tested for their ability to increase cAMP levels in HEK293 cells stably
expressing GPRl19.
Fig. 3.6 and Table 3.4 demonstrate the agonist activity of different oleoyl
amides as compared to OEA. In HEK293 cells stably expressing GPRl19, OLDA,
Oleamide, and OEA increased cAMP levels, with similar ECso and Emax values. On
the contrary, oleoyl alanine, oleoyl glycine, and oleoyl GABA failed to activate
GPRl19 with concentrations up to 10 !J.M.
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Figure 3.1. Z' factor determination. Open symbols represent positive controls (cells

stimulated with 10 IlM AR231453), while solid symbols represent negative controls
(basal level). The Z' factor was calculated to be 0.68 using 55 basal and stimulated signal
points.
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Figure 3.2. DMSO tolerance. HEK293 cells stably expressing GPRl19 was treated with
different concentrations of DMSO. Delta F % was calculated using the following
fonnula: Delta F % = [(standard or sample ratio - ratio of the negative control) / ratio of
the negative control] x 100. Values represent the mean ± S.E.M. of three independent
experiments, each perfonned in duplicate.
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Figure 3.3. Pharmacological testing of known GPR119 agonists. HEK293 stably

expressing GPRl19 were treated with GPR119 agonists AR231453, oleoylethanolamide,
and PSN632408 for 30 minutes. Results are expressed as actual cAMP levels determined
from the standard curve. Values represent the mean ± S.E.M. of three independent
experiments, each performed in duplicate.
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Figure 3.4. The effects of acyl chain unsaturation on the ability of fatty acid
ethanolamides to activate GPR119. HEK293 stably expressing GPRl19 were treated
with OEA, PEA, and AEA for 30 minutes. Results are expressed as actual cAMP levels
determined from the standard curve. Values represent the mean ± S.E.M. of three
independent experiments, each performed in duplicate.
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Figure 3.5. The effects of acyl chain unsaturation on the ability of fatty acid
ethanolamides to activate GPR119. HEK293 stably expressing GPRl19 were treated
with Oleoyl ethanolamide (OEA), Linoleoyl ethanolamide (LEA), Dihomo-gammalinolenoyl ethanolamide (DLEA), Docosatetra-7Z, 1OZ, 13Z, 16Z-enoyl ethanol amide
(DTEA), Eicosapentaenoyl ethanol amide (EPEA) and Docosahexaenoyl ethanolamide
(DHEA) for 30 minutes. Results are expressed as actual cAMP levels determined from
the standard curve. Values represent the mean ± S.E.M. of three independent experiments
each performed in duplicate.
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Figure 3.6. The effects of different head groups on the ability of oleoyl amides to
activate GPR119.

HEK293 stably expressing GPRl19 were treated with OLDA,

oleamide, OEA, oleoyl alanine, oleoyl glycine, and oleoyl GABA for 30 minutes. Results
are expressed as actual cAMP levels determined from the standard curve. Values
represent the mean ± S.E.M. of three independent experiments each performed in
duplicate.
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Table 3.1. Effect of known GPR1l9 agonists on increasing cAMP in HEK293 cells
stably expressing GPRl19.
Drug

ECso (95% CI) (IJM)

AR231453

.027 (0.013 to 0.058)

PSN632-408

1.28 (1.10 to 1.49)

Oleoylethanolamide

1.08 (0.59 to 1.98)

CI, confidence interval. Data shown are from three experiments each performed in
duplicate.

50

Table 3.2. The effects of synthetic cannabinoids on increasing cAMP levels in
HEK293 cells stably expressing GPR119.

Drug

ECso (95% CI) (11M)

CP-55,950

NR

HU-210

NR

WIN55,212-2

NR

CI, confidence interval. NR, No response. Data shown are from experiments each
performed in duplicate.
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Table 3.3. The effects of acyl chain unsaturation on the ability of fatty acid
ethanolamides to increase cAMP levels in HEK293 cells stably expressing GPR119.

Drug

EC so (95% CI) (,..M)

Linoleoyl ethanol amide

4.33 (1.48 to 12.7)

Docosahexaenoyl ethanol amide

NR

Dihomo-y-linolenoyl ethanolamide

8.38 (0.91 to 77.2)

Docosatetra-7Z,1 OZ, 13Z, 16Z-enoyl
ethanolamide

6.02 (1.93 to 18.8)

Eicosapentaenoyl ethanolamide

5.09 (0.59 to 44.0)

Oleoylethanolamide

1.08 (0.59 to 1.98)

Anandamide

2.62 (0.36 to 19.3)

Palmi toylethanolamide

6.82 (1.10 to 42.5)

CI, confidence interval. NR, No response. Data shown are from at least three experiments
each performed in duplicate.
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Table 3.4. The effects of different head groups on the ability of oleoyl amides to
increase cAMP levels in HEK293 cells stably expressing GPR119.

Drugs

EC so (95% CI) (IlM)

OLDA

1.17 (0.98 to 1.38)

Oleamide

1.28 (1.1 0 to 1.49)

OEA

1.08 (0.59 to 1.98)

Oleoyl alanine

NR

Oleoyl glycine

NR

Oleoyl GABA

NR

CI, confidence interval. NR, No response. Data shown are from experiments each
performed in duplicate.
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DISCUSSION

Agonist binding to GPR 119 leads to Gs coupling and activation of adenylate
cyclase (Chu et aI., 2007b). As a result, there is an increase in intracellular cAMP levels
which was measured as a decrease in HTRF signal in this study. We have shown that the
HTRF HiRange cell-based cAMP assay is a suitable technology for screening ligands that
may act on GPRl19.
The Z'factor is a standard statistical parameter used to evaluate the robustness of
a screening assay (Zhang et aI., 1999). The Z'factor value can range between 0 and 1,
with values approaching 1 indicates excellent assay robustness. A value of greater than
0.5 indicates a suitable difference between signal and background values with low
variability. In this study we determined Z'factor according to the methods published
previously (Zhang et aI., 1999). The calculated Z'factor for the HTRF HiRange cellbased cAMP assay was 0.68. These results demonstrated that this assay is robust and
suitable for screening ligands that activate GPRl19 since the determined Z'factor is
greater than 0.5.
Since most chemical compound libraries come pre-dissolved in dimethyl
sulfoxide (DMSO), it is critical to determine the maximum concentration that a
compound can be screened before DMSO reaches a concentration that is too high to be
tolerated by the assay. Therefore, we determined the effect of DMSO on the HTRF
HiRange cAMP cell-based assay. We tested DMSO at a variety of concentrations and the
results showed that the assay can tolerate DMSO up to 1 %. These data indicate that the
assay is suitable for screening ligands that may act on GPRl19 at a DMSO concentration
of less than 1 %.
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To validate that the HTRF HiRange cell-based cAMP assay is suitable for
screening ligands that may activate GPRI19, we performed concentration-response
studies for three previously reported GPR119 agonists. The rank order of potencies of
these three known GPR119 agonists in enhancing cAMP levels in GPRl19-expressing
HEK293 cells was AR231453 > OEA = PSN632408. These data are consistent with
previous reports regarding the potency of these GPR119 agonists (Overton et aI., 2006;
Semple et aI., 2008). These results also confirmed the suitability ofHTRF HiRange cellbased cAMP assay for screening potential novel ligands for GPRI19.
Since the closest relatives of GPR 119 are the cannabinoid receptors (Godlewski et
aI., 2009), in this study we tested the three prototypic synthetic cannabinoid agonists CP55,940, HU-210, and WIN-55,212-2 for their potential activity towards GPR119 using
the HTRF HiRange cAMP cell-based assay. Similar to the data reported by Overton et aI.
(2006), our study showed that the classical cannabinoid agonist HU-21O, the nonclassical, the bicyclic cannabinoid agonist CP-55,940, and the aminoalkylindole WIN55,212-2 do not activate GPRI19.
Recently, the fatty acid ethanolamide OEA has been reported to be a putative
endogenous ligand for GPR119 (Overton et aI., 2006). Overton and coworkers have also
tested the endogenous cannabinoid agonist AEA and the saturated fatty-acid
ethanol amide PEA for GPR119 activity in a yeast-based assay. Their results showed that
OEA was the most efficacious, followed by PEA and then AEA. As shown by the
concentration-response curves in this study, our results on OEA, PEA, and AEA are very
much consistent with those reported by Overton et aI. (2006).
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Previously, based on the data with OEA, PEA, and AEA, Overton and co-workers
have proposed that unsaturation in fatty acid aryl chain might be important for activating
GPRl19 (Overton et aI., 2006) .
In this study, we report for the first time the structure activity relationship for
GPRl19 activation on a subset of fatty acid ethanolamides, including linoleoyl
ethanolamide (LEA), dihomo-gamma-linolenoyl ethanolamide (DLEA), docosatetra7Z,1 OZ, 13Z, 16Z-enoyl ethanolamide (DTEA), eicosapentaenoyl ethanol amide (EPEA),
and docosahexaenoyl ethanolamide (DHEA). Overall, our new data in the present study
provide direct evidence to further support the hypothesis that unsaturation in the acyl
chain of fatty acid ethanolamides affects the ability of these compounds to activate
GPRl19.
Our results indicate that increasing unsaturation reduces the ability of these
ligands to activate GPRl19; with compounds containing 1-3 double bonds have
significantly higher efficacy and potency than those compounds containing 4-6 double
bonds.
Chu et ai. (2010) reported that a diverse set oflipid amides, including OLDA and
oleamide, activate GPRl19. Thus, they suggested that there is a broad permissiveness in
the amine-derived moieties (the head groups) oflipid amides for being an agonist for
GPR119 (Chu et aI., 2010). In the present study, we demonstrated that both OLDA and
oleamide activate GPRl19, with similar potency and efficacy as OEA. These data are
consistent with the findings of Chu et ai. (2010) and confirm the notion that there is a
considerable level of permissiveness in the head group of oleoyl amides.
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However, in the current study, we also demonstrated that oleoyl alanine, oleoyl
glycine, and oleoyl GABA were unable to activate GPRl19. These data suggest that
although there are certain levels of permissiveness, in order to activate GPRl19, there are
also certain structural requirements for the head groups of oleoyl amides. An interesting
observation is that all three compounds (oleoyl alanine, oleoyl glycine, and oleoyl
GABA) that failed to activate GPRl19 have a carboxcylic group. This suggests that the
reason that these ligands failed to activate GPRl19 might be due to either the spatial
hindrance or the acidic nature of the carboxylate group.
Among the three oleoyl amides that activated GPRl19, both OLDA and OEA
contain hydrogen donating hydroxyl groups in their structure for potential hydrogen
bonding interactions with the receptor. This indicates that these hydrogen donating
groups might be important for their ability to interact and activate GPRl19.
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